A61K 40/4216
Receptors for colony stimulating factors [csf]
Official title: {Receptors for colony stimulating factors [CSF]}
A61K40/4216 (Receptors for colony stimulating factors [csf]) appears on 8 US grants and 17 published applications in this corpus.
Search patents in A61K- Granted patents
- 8
- Published applications
- 17
- Assignees
- 11
- Inventors
- 38
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 2 | 4 |
| 2021 | 1 | 1 |
| 2022 | 0 | 2 |
| 2023 | 1 | 0 |
| 2024 | 1 | 6 |
| 2025 | 2 | 0 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Therapeutic agents28 Apr 2026US 12,612,445 B2King's College London
- Therapeutic agents30 Dec 2025US 12,509,499 B2King's College London
- Synthetic immune receptors and methods of use thereof8 Apr 2025US 12,269,859 B2Angeles Therapeutics, Inc.
- Cell therapy with lentiviral transduced CSF2RA transgene in the treatment of hereditary pulmonary alveolar proteinosis23 Jul 2024US 12,043,844 B2Children's Hospital Medical Center
- Therapeutic agents31 Oct 2023US 11,802,143 B2King's College London
- Polynucleotides, polypeptides, cells, and compositions comprising synthetic immune receptors with methods of manufacture and treatment18 Jun 2026US 2026/0167693 A1Angeles Therapeutics, Inc.
- Chimeric antigen receptor specific to cd11721 May 2026US 2026/0137783 A1Crispr Therapeutics AG
- Anti-csf1r car expressing lymphocytes for targeted tumor therapy17 Oct 2024US 2024/0342282 A1Ludwig-Maximilians-Universitat Munchen
- Therapeutic agents11 Jul 2024US 2024/0228576 A1King's College London
- Chimeric Cytokine Receptors18 Apr 2024US 2024/0122979 A1
Most cited
By later US patents
- Therapeutic agents5US 10,703,794 B2King's College London · 2020
- Therapeutic agents4US 10,865,231 B2King's College London · 2020
- Therapeutic agents2US 10,899,818 B2King's College London · 2021
- Therapeutic agents2US 11,802,143 B2King's College London · 2023
- Synthetic immune receptors and methods of use thereof1US 12,269,859 B2Angeles Therapeutics, Inc. · 2025